Product Candidate
Discovery
Preclinical
PHASE 1
PHASE 2
PHASE 3
MARKET

Virology: Liver

HCV Protease Inhibitor
Glecaprevir-containing pangenotypic 2-DAA combo
mavyret
HBV Core Inhibitor
EDP-514Viremic HBV patients
HBVCore Inhibitor
EDP-514NUC-suppressed HBV patients
HBVRNA Destabilizer
EDP-721

Virology: Respiratory

RSVN-Protein Inhibitor
EDP-938RSVP
RSVN-Protein Inhibitor
EDP-938RSVPEDs
RSVN-Protein Inhibitor
EDP-938RSVTx
RSVL-Protein Inhibitor
hMPV Non-Fusion Inhibitor
COVID-19 SARS-CoV-2 Inhibitor
EDP-235

Discovery or Preclinical

RSV, HBV, Other

Out-license

NASH FXR Agonists
EDP-305 (Phase 2), EDP-297 (Phase 1)

*Fixed-dose combination contains glecaprevir and AbbVie's NS5A inhibitor, pibrentasvir. Marketed by AbbVie as MAVYRET (U.S.) and MAVIRET (ex-U.S.).